Nuvectis Pharma (NVCT) Current Assets (2021 - 2026)

Nuvectis Pharma has reported Current Assets for 6 years, with the latest figure at $25.4 million in Q1 2026.

• Quarterly Current Assets fell 15.76% year-over-year to $25.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.4 million (down 15.76% YoY) and the FY2025 annual result came in at $31.7 million, up 70.41% from the prior year.
• Current Assets eased to $25.4 million in Q1 2026 per NVCT's latest filing, from $31.7 million in the prior quarter.
• Over five years, Current Assets peaked at $35.6 million in Q3 2025 and troughed at $14.2 million in Q2 2022.
• A 5-year average of $22.6 million and a median of $20.4 million in 2022 frame the typical range for Current Assets.
• The sharpest annual moves came in 2022 and 2024: Current Assets jumped 249.82% in 2022, then decreased 26.63% in 2024.
• Over 5 years, Current Assets stood at $20.4 million in 2022, then declined by 5.98% to $19.2 million in 2023, then retreated by 3.01% to $18.6 million in 2024, then jumped by 70.41% to $31.7 million in 2025, then fell by 19.9% to $25.4 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $25.4 million, $31.7 million, and $35.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.